Press releases
-
-
December 15, 2009 - Alethia Biotherapeutics announces the nomination of Dr. Michael Berendt to the Board of Directors
-
December 7, 2009 - Alethia Biotherapeutics in-licenses a peptide for imaging of solid tumors in vivo and announces positive pre-clinical results of AB-16B5 in prostate and breast cancer
-
November 30, 2009 - Alethia Biotherapeutics collaborators at the NRC-BRI publish results in Oncogene on the role of secreted clusterin as an important mediator of EMT
-
May 26 2009 - Alethia Biotherapeutics extends its collaborative agreement with Biosite for monoclonal antibody development
-
May 6, 2009 - Alethia Biotherapeutics exercises its license option with NRC-BRI
-
April 23, 2009 - Alethia Biotherapeutics closes a $2.2 M financing
-
February 17, 2009 - Yves Cornellier, president and CEO Alethia Biotherapeutics, nominated to the Board of Directors of Montreal in Vivo
